6:28 PM
 | 
Oct 18, 2012
 |  BC Extra  |  Company News

BioCryst, Presidio combining

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) will acquire Presidio Pharmaceuticals Inc. (San Francisco, Calif.) in a stock deal. The combined company will launch with a new name to focus on HCV and hereditary angioedema (HAE). BioCryst will issue 24.5 million shares to Presidio shareholders, which values Presidio at $100.7 million based on BioCryst's Wednesday close of $4.11. The...

Read the full 266 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >